Lv5
928 积分 2024-09-11 加入
Combinatorial strategies to target RAS-driven cancers
1个月前
已完结
Sotorasib in combination with alpelisib in patients with KRAS G12C–mutated solid tumors: Phase 1b results from the CodeBreaK 101 study
1个月前
已关闭
Leveraging Model Integrated Bioequivalence (MIBE) to Address Regulatory Concerns and Waive Repeat Bioequivalence Studies—A Case Study with Clopidogrel
2个月前
已完结
Endpoint Exposure‐Response Analyses in the Presence of Concurrent Dose Modification During Clinical Trials
3个月前
已完结
Navigating therapeutic challenges: Voriconazole pharmacokinetics and CYP2C19 genetic polymorphism—A case report and literature review
4个月前
已完结
Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology
4个月前
已完结
Approval of Upadacitinib in Pediatric Patients with Active Polyarticular Juvenile Idiopathic Arthritis or Active Psoriatic Arthritis: A Regulatory Perspective
4个月前
已完结
Ivarmacitinib, a selective Janus kinase 1 inhibitor, in patients with moderate-to-severe active rheumatoid arthritis and inadequate response to conventional synthetic DMARDs: results from a phase III randomised clinical trial
5个月前
已完结
A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata
5个月前
已完结
Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial
5个月前
已完结
皖公网安备34019202002308
